<b>Cambritaxestat</b><b> Reduces Tumor Growth</b> in mGC models
收藏NIAID Data Ecosystem2026-05-10 收录
数据链接：
官方服务：
资源简介：
The study confirmed the efficacy of therapy targeting the ATX/LPA axis in advanced GC. Cambritaxestat, an ATX inhibitor with oral bioavailability and tolerability, is a promising candidate for combination with standard chemotherapy or antiangiogenic therapies, helping to overcome resistance and adapt conventional strategies.
创建时间：
2025-10-30
